课题基金 / 基金详情

Malaria Vaccine: Pfs230

Malaria Vaccine: Pfs230
疟疾疫苗：Pfs230
批准号：
8745458
负责人：
Patrick Duffy
金额：
$168.11万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8745458
关键词：
AnimalsAntibodiesAreaBiological AssayComplementCyclic GMPDataEscherichia coliGermGoalsHumanImmune SeraMalariaMalaria VaccinesMembraneParasitesPichiaPopulationProductionProteinsRecombinantsSurfaceVaccinesWheatbaseburden of illnessexpression cloningfeedingsuccesstransmission processvaccine evaluation

项目摘要

项目成果

Patrick Duffy的其他基金

相似基金

相关文献

中文摘要
翻译
在成功鉴定小麦胚芽表达的Pfs230结构域的基础上，重组Pfs230结构域也在巴斯德毕赤酵母和大肠杆菌中得到了表达。在体外标准的膜喂养试验中，针对这些结构域的抗血清以补体依赖的方式显示出强大的传播阻断活性。对多个表达克隆的重组Pfs230的产量、产量和功能抗体的诱导进行了评估。选择了一个毕赤酵母表达克隆，制备了cGMP级重组Pfs230。目前的努力集中在生产cGMP级Pfs230-EPA，将其与Pfs25-EPA疫苗结合，并作为潜在有效的传播阻断疫苗在人类身上进行测试。
英文摘要
Built on success in evaluating the wheat germ-expressed Pfs230 domains, recombinant Pfs230 domains were also expressed in P. pastoris and E. coli. Antisera raised against these domains demonstrated potent transmission blocking activities in an ex vivo standard membrane feeding assay, in a complement-dependent manner. Multiple expression clones were evaluated for their recombinant Pfs230 production yield and induction of functional antibodies. A Pichia expression clone was selected, and cGMP grade recombinant Pfs230 was manufactured. The current efforts are focused on generating cGMP grade Pfs230-EPA, to be combined with Pfs25-EPA vaccine and tested in humans as potentially effective transmission blocking vaccine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Malaria Surveillance and Research Studies in Liberia and Guinea-Conakry
Malaria Transmission Blocking Vaccine Discovery
Malaria Pathogenesis in young children and vaccine discovery
Malaria Vaccine: Pfs25-rEPA
海外基金